Analysis of the Effectiveness of Neoadjuvant Chemotherapy in the Treatment of Colon Cancer Locally Advanced (ELECLA)

Phase 2

• Conditions: Locally Advanced Colon Cancer
• Interventions: Combination Product: CAPECITABINE AND OXALIPLATIN

• Registration Number: NCT04188158
• Lead Sponsor: Universidad de León

Brief Summary

Effectiveness analysis of neoadjuvant chemotherapy in the treatment of locally advanced colon cancer. ELECLA trial

Detailed Description

Participants in this study selected patients according to homogeneous inclusion criteria and will be treated either with a uniform protocol of neoadjuvant chemotherapy, surgery and complementary chemotherapy (intervention group), or with the standard scheme of postoperative surgery and chemotherapy (control group ). All patients will be studied basally through clinical examinations and radiological and endoscopic tests usually used to reach the diagnosis of Locally Advanced Colon Cancer . In the group of patients receiving neoadjuvant treatment, the CT scan will be repeated after the completion of preoperative chemotherapy to restage the disease and quantify the degree of tumor response.

Finally, the project tries to determine whether the neoadjuvant treatment scheme increases disease-free survival (SLE) at 2 and 5 years and overall survival (OS) at 5 years. Likewise, the toxicity derived from chemotherapy treatment and perioperative morbidity and mortality will be analyzed to evaluate the feasibility and safety of the therapeutic procedure. The rate of completion of chemotherapy in both groups will also be compared.

Study Timeline

• Study Start: 2017-03-10
• Study First Submitted: 2019-11-25
• Status Verified: 2019-12
• Study First Submitted QC: 2019-12-04
• Last Update Submitted: 2019-12-04
• Study First Posted: 2019-12-05
• Last Update Posted: 2019-12-05
• Primary Completion: 2023-05-10
• Study Completion: 2024-03-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 238

Inclusion Criteria

• CLINICS

  1. Histological confirmation of colon adenocarcinoma.
  2. Patients of both sexes with age over 18 years.
  3. Good general condition of the patient (Karnofsky> 60% or ECOG (Eastern Cooperative Oncology Group) <2).
  4. Analytical at the time of inclusion with figures of Hemoglobin> 10 g / dL; Leukocytes> 3.0 109 / L, Platelets> 100,000, Glomerular Filtration> 50 ml / min and Total Bilirubin <25 micromol / l.
  5. Absence of contraindication for chemotherapy.
  6. Acceptance and signature of the Informed Consent.

• OF IMAGE

  1. Radiological signs, evaluated by CT, of T4 or T3 tumor infiltration> 5 mm of transmural invasion.
  2. With or without lymph node involvement by CT.
  3. No metastatic involvement in other organs (M0).
  4. Radiologically resectable disease. REFERENCES TO THE TREATMENT
  <!-- -->
  1. That they will undergo elective surgery with curative intent (R0).

Exclusion Criteria

• 1. Important comorbidity, uncontrolled angina or a history of acute myocardial infarction in the last 6 months.

  2. Personal history of another malignancy in the last 5 years, with the exception of melanoma.

  3. Uncontrolled infection 4. Pregnancy or lactation. 5. Peripheral neuropathy> grade 1. 6. Rectum cancer (<15 cm of the anal margin or below peritoneal reflection). 7. Presence of distant metastasis or peritoneal carcinomatosis. 8. Intestinal obstruction. 9. Existence of microsatellite instability 10. Refusal to participate or to give written consent 11. Impossibility, at the investigator's discretion, to understand the purpose of the study or to comply with its procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	CAPECITABINE AND OXALIPLATIN	Surgery + 8 cycles XELOX
Intervention Group	CAPECITABINE AND OXALIPLATIN	3 cycles XELOX + Surgery+ 5 cycles XELOX

Primary Outcome Measures

Name	Time	Method
Disease-free survival (SLE) at 2 years	From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.	To determine whether the proposed treatment with neoadjuvant chemotherapy, surgery and complementary chemotherapy increases the disease-free survival (SLE) at 2 years postoperatively, compared with standard treatment, surgery and complementary chemotherapy.

Secondary Outcome Measures

Name	Time	Method
To assess whether neoadjuvant chemotherapy, surgery and complementary chemotherapy increases SLE 5 years postoperatively, compared to standard treatment of surgery and complementary chemotherapy	From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.	From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.
To evaluate whether neoadjuvant chemotherapy, surgery and complementary chemotherapy increase OS at 2 and 5 years postoperatively, in comparison with standard treatment of surgery and complementary chemotherapy.	From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.	From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.
To compare the postoperative morbidity and mortality of the neoadjuvant treatment in relation to the standard treatment	From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.	From the inclusion of the patient in the study to 5 years of follow-up or his death, whichever comes first.

Trial Locations

Locations (1)

Complejo Asistencial Universitario de Leon; 🇪🇸 León, Spain